National Cancer Institute research identified a gene named IFNL4 that interferes with the body's clearance of infection with the hepatitis C virus. Researchers said the gene predicts the outcome of HCV treatments among African-Americans better than standard tests and may explain why some patients do not respond well to interferon therapy.

Related Summaries